Want to see DARE full AI Analyst Report?
DARE Stock Chart & Stats
$0.75
$0.04(3.13%)
At close: 4:00 PM EDT
$0.75
$0.04(3.13%)
Day’s Range― - ―
52-Week Range$0.69 - $3.78
Previous Close$1.33
Volume168.05K
Average Volume (3M)662.44K
Market Cap
$14.56M
Enterprise Value$25.56
Total Cash (Recent Filing)$12.62M
Total Debt (Recent Filing)$6.76M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 05, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding19,669,083
10 Day Avg. Volume544,566
30 Day Avg. Volume662,437
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)75.90
Price to Sales (P/S)209.43
P/FCF Ratio-21.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside1233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$2.10M
Bulls Say, Bears Say
Bulls Say
Initial CommercializationThe first direct product launch gives Daré a foundation for building recurring commercial revenue and gaining commercialization experience. It also supports a broader portfolio strategy beyond dependence on clinical milestones or licensing transactions.
Clinical Pipeline ProgressPositive interim Phase III data materially advances Ovaprene toward potential regulatory submission and commercialization. If sustained, the program could create a differentiated women’s-health product and a future royalty or product-revenue stream.
Non-Dilutive Pipeline FundingExternal non-dilutive funding reduces the amount of shareholder capital required for selected research programs and validates outside support for the pipeline. This can extend development capacity while preserving resources for commercial execution.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow shows that the current business does not yet fund its own development and commercialization. Continued burn increases dependence on financing, partnerships, or successful product launches to maintain operations.
Weak Balance Sheet And LossesNegative equity and large operating losses indicate cumulative financial strain and limited balance-sheet flexibility. The absence of stable positive gross profit makes it difficult to absorb setbacks and raises the importance of achieving sustainable commercial scale.
Financing And Regulatory Execution RiskReliance on equity-linked funding can dilute existing holders and signals that internal cash generation remains insufficient. Nasdaq compliance risk may further constrain access to public capital, while regulatory and launch timing uncertainty could delay expected pipeline revenue.
Daré Bioscience News
DARE FAQ
What was Daré Bioscience Inc’s price range in the past 12 months?
Daré Bioscience Inc lowest stock price was $0.69 and its highest was $3.78 in the past 12 months.
What is Daré Bioscience Inc’s market cap?
Daré Bioscience Inc’s market cap is $14.56M.
When is Daré Bioscience Inc’s upcoming earnings report date?
Daré Bioscience Inc’s upcoming earnings report date is Nov 05, 2026 which is in 61 days.
How were Daré Bioscience Inc’s earnings last quarter?
Daré Bioscience Inc released its earnings results on Aug 13, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.297 by $0.097.
Is Daré Bioscience Inc overvalued?
According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued.
Does Daré Bioscience Inc pay dividends?
Daré Bioscience Inc does not currently pay dividends.
What is Daré Bioscience Inc’s EPS estimate?
Daré Bioscience Inc’s EPS estimate is -0.14.
How many shares outstanding does Daré Bioscience Inc have?
Daré Bioscience Inc has 19,669,083 shares outstanding.
What happened to Daré Bioscience Inc’s price movement after its last earnings report?
Daré Bioscience Inc reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.297. Following the earnings report the stock price went down -32.117%.
Which hedge fund is a major shareholder of Daré Bioscience Inc?
Currently, no hedge funds are holding shares in DARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daré Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
DARE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call described meaningful operational and clinical progress — a first product launch, an approaching prescription product with early prescription activity, positive Phase III interim data for Ovaprene, and non-dilutive funding supporting R&D. However, these positives are balanced by constrained near-term financials: modest Q2 revenue ($200k), limited cash ($12.6M) with a slight working capital deficit, a sizable deferred grant liability (~$15M), and ongoing net losses. Regulatory nuance around Ovaprene completers and the fact that DARE-VVA1 is not yet dispensing also add execution and timing risk. Overall, the update reflects promising commercial and clinical momentum but with material near-term financial and execution challenges.View all DARE earnings summariesDARE Stock 12 Month Forecast
Average Price Target
$10.00
▲(1233.33% Upside)
Technical Analysis
Vyome Holdings
―
Lunai Bioworks
―
Passage Bio
―
Neurosense Therapeutics Ltd.
―
Boundless Bio Inc.
―
Ownership Overview
5.50% Insiders
2.95% Mutual Funds
0.12% Other Institutional Investors
87.97% Public Companies and
Individual Investors